机构：[1]Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China;中山大学肿瘤防治中心[2]Fujian Med Univ, Fujian Union Hosp, Dept Pharm, Changzheng Rd 1, Fuzhou, Fujian, Peoples R China;[3]Kunming Med Coll, Yuxi Peoples Hosp, Dept Pharm, Nieer Rd 21, Kunming, Yunnan, Peoples R China;[4]Shanghai Jiao Tong Univ, Ren Ji Hosp, Med Decis & Econ Grp, Dept Pharm,Sch Med, South Campus, Shanghai, Peoples R China
出处：
ISSN：
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2017]版：
大类|1 区医学
小类|1 区肿瘤学
最新[2023]版：
大类|1 区医学
小类|1 区肿瘤学
第一作者：
第一作者机构：[1]Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China;[2]Fujian Med Univ, Fujian Union Hosp, Dept Pharm, Changzheng Rd 1, Fuzhou, Fujian, Peoples R China;[3]Kunming Med Coll, Yuxi Peoples Hosp, Dept Pharm, Nieer Rd 21, Kunming, Yunnan, Peoples R China;[4]Shanghai Jiao Tong Univ, Ren Ji Hosp, Med Decis & Econ Grp, Dept Pharm,Sch Med, South Campus, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Chen Gong,Liu Maobai,Li Te,et al.Bevacizumab in addition to chemotherapy first-line for right-side metastatic colorectal cancer: A cost-effectiveness analysis.[J].JOURNAL OF CLINICAL ONCOLOGY.2017,35(4):-.
APA：
Chen, Gong,Liu, Maobai,Li, Te&Wu, Bin.(2017).Bevacizumab in addition to chemotherapy first-line for right-side metastatic colorectal cancer: A cost-effectiveness analysis..JOURNAL OF CLINICAL ONCOLOGY,35,(4)
MLA：
Chen, Gong,et al."Bevacizumab in addition to chemotherapy first-line for right-side metastatic colorectal cancer: A cost-effectiveness analysis.".JOURNAL OF CLINICAL ONCOLOGY 35..4(2017):-
医学